76
Views
0
CrossRef citations to date
0
Altmetric
Brief report

Intended use for a neoadjuvant chemoradiation response prediction test for locally advanced esophageal adenocarcinoma: a survey analysis of thoracic surgeons in the US

, , , , , , , & show all
Pages 1003-1007 | Accepted 02 Mar 2015, Published online: 25 Mar 2015

References

  • Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30
  • Vial M, Grande L, Pera M. Epidemiology of adenocarcinoma of the esophagus, gastric cardia, and upper gastric third. Recent Results Cancer Res 2010;182:1-17
  • Ajani JA. NCCN Clinical Practice Guidelines in Oncology: Esophageal and Esophagogastric Junction Cancers Version 2.2013. 2013
  • Shridhar R, Imani-Shikhabadi R, Davis B, et al. Curative treatment of esophageal cancer; an evidenced based review. J Gastrointest Cancer 2013;44:375-84
  • Leichman LP, Goldman BH, Bohanes PO, et al. S0356: a phase II clinical and prospective molecular trial with oxaliplatin, fluorouracil, and external-beam radiation therapy before surgery for patients with esophageal adenocarcinoma. J Clin Oncol 2011;29:4555-60
  • van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. New Engl J Med 2012;366:2074-84
  • van Meerten E, Muller K, Tilanus HW, et al. Neoadjuvant concurrent chemoradiation with weekly paclitaxel and carboplatin for patients with oesophageal cancer: a phase II study. Br J Cancer 2006;94:1389-94
  • Bollschweiler E, Metzger R, Drebber U, et al. Histological type of esophageal cancer might affect response to neo-adjuvant radiochemotherapy and subsequent prognosis. Ann Oncol 2009;20:231-8
  • Rohatgi P, Swisher SG, Correa AM, et al. Characterization of pathologic complete response after preoperative chemoradiotherapy in carcinoma of the esophagus and outcome after pathologic complete response. Cancer 2005;104:2365-72
  • Talsma K, van Hagen P, Grotenhuis BA, et al. Comparison of the 6th and 7th Editions of the UICC-AJCC TNM Classification for Esophageal Cancer. Ann Surg Oncol 2012;19:2142-8
  • Ajani JA, Barthel JS, Bentrem DJ, et al. Esophageal and esophagogastric junction cancers. J Natl Compr Canc Netw 2011;9:830-87
  • Ajani J. Validated biomarker signatures that predict pathologic response to preoperative chemoradiation therapy (CTRT) with high specificity and desirable sensitivity levels in patients with esophageal cancer (EC). J Clin Oncol 2011;29(Suppl):abstr 4027
  • Rosen DG, Shan W, Lassen N, et al. Prospective prediction of resistance to neoadjuvant therapy in patients with locoregional esophageal adenocarcinoma. Gastrointestinal Cancer: Targets and Therapy 2015;5:53-9

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.